FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2004149792> ?p ?o ?g. }

• W2004149792 endingPage "567" @default.
• W2004149792 startingPage "557" @default.
• W2004149792 abstract "To assess dosing, preliminary safety, and efficacy of canakinumab, a fully human anti-interleukin-1β (anti-IL-1β) antibody, in children with systemic juvenile idiopathic arthritis (JIA) and active systemic features.In this phase II, multicenter, open-label, dosage-escalation study, children with systemic JIA who were ≥4 years of age, had fever, and were receiving ≤0.4 mg/kg/day of corticosteroids were administered a single subcutaneous dose of canakinumab, 0.5-9 mg/kg of body weight, and were redosed upon relapse. Response to treatment was assessed according to an adaptation of the American College of Rheumatology (ACR) pediatric criteria for improvement.A total of 23 children ages 4-19 years with active disease were enrolled. Of these, 1 patient was excluded from analysis, and 3 of the reenrolled patients were included twice in the efficacy analysis. By day 15 of the first treatment cycle, 15 of 25 patients (60%) had achieved an adapted ACR Pediatric 50 response, with 4 of them achieving inactive disease status. Response was sustained over time, with 11 of 13 patients able to maintain their response throughout the study. In 8 of the 11 responders who had been receiving steroids at baseline, the steroid dosage was decreased from a mean of 0.38 mg/kg/day to 0.13 mg/kg/day over the first 5 months, and 4 of them were able to discontinue steroids. At a dose of 4 mg/kg of canakinumab given subcutaneously every 4 weeks, the median percentage of patients predicted to relapse within 4 weeks was estimated to be 6% (95% confidence interval 1-21). Therapy was generally well tolerated and few patients experienced injection-site reactions.Canakinumab has a promising preliminary safety and efficacy profile in this limited cohort. Based on the findings of this trial, further studies in a larger population of children with systemic JIA are warranted." @default.
• W2004149792 created "2016-06-24" @default.
• W2004149792 creator A5000210931 @default.
• W2004149792 creator A5020507966 @default.
• W2004149792 creator A5027612338 @default.
• W2004149792 creator A5028693685 @default.
• W2004149792 creator A5029874460 @default.
• W2004149792 creator A5036158155 @default.
• W2004149792 creator A5037248383 @default.
• W2004149792 creator A5053583284 @default.
• W2004149792 creator A5055180780 @default.
• W2004149792 creator A5060906323 @default.
• W2004149792 creator A5070113073 @default.
• W2004149792 creator A5079738832 @default.
• W2004149792 creator A5080140512 @default.
• W2004149792 creator A5091090377 @default.
• W2004149792 date "2012-01-27" @default.
• W2004149792 modified "2023-10-14" @default.
• W2004149792 title "A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features" @default.
• W2004149792 cites W1565787660 @default.
• W2004149792 cites W1967173230 @default.
• W2004149792 cites W1972763246 @default.
• W2004149792 cites W1998366883 @default.
• W2004149792 cites W2007470619 @default.
• W2004149792 cites W2012210739 @default.
• W2004149792 cites W2026404803 @default.
• W2004149792 cites W2033023137 @default.
• W2004149792 cites W2046419496 @default.
• W2004149792 cites W2046440869 @default.
• W2004149792 cites W2051611327 @default.
• W2004149792 cites W2052604117 @default.
• W2004149792 cites W2054276574 @default.
• W2004149792 cites W2062143882 @default.
• W2004149792 cites W2065287600 @default.
• W2004149792 cites W2072054779 @default.
• W2004149792 cites W2073700972 @default.
• W2004149792 cites W2081543974 @default.
• W2004149792 cites W2096905901 @default.
• W2004149792 cites W2120852203 @default.
• W2004149792 cites W2125372614 @default.
• W2004149792 cites W2127192427 @default.
• W2004149792 cites W2129424027 @default.
• W2004149792 cites W2131963039 @default.
• W2004149792 cites W2134389576 @default.
• W2004149792 cites W2138049450 @default.
• W2004149792 cites W2142960568 @default.
• W2004149792 cites W2144016275 @default.
• W2004149792 cites W2149374693 @default.
• W2004149792 cites W2150411992 @default.
• W2004149792 cites W2154552358 @default.
• W2004149792 cites W2156584537 @default.
• W2004149792 cites W2166106092 @default.
• W2004149792 cites W2171499120 @default.
• W2004149792 cites W4243137983 @default.
• W2004149792 cites W4244548826 @default.
• W2004149792 cites W4255497843 @default.
• W2004149792 cites W4323284479 @default.
• W2004149792 doi "https://doi.org/10.1002/art.33342" @default.
• W2004149792 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21953497" @default.
• W2004149792 hasPublicationYear "2012" @default.
• W2004149792 type Work @default.
• W2004149792 sameAs 2004149792 @default.
• W2004149792 citedByCount "174" @default.
• W2004149792 countsByYear W20041497922012 @default.
• W2004149792 countsByYear W20041497922013 @default.
• W2004149792 countsByYear W20041497922014 @default.
• W2004149792 countsByYear W20041497922015 @default.
• W2004149792 countsByYear W20041497922016 @default.
• W2004149792 countsByYear W20041497922017 @default.
• W2004149792 countsByYear W20041497922018 @default.
• W2004149792 countsByYear W20041497922019 @default.
• W2004149792 countsByYear W20041497922020 @default.
• W2004149792 countsByYear W20041497922021 @default.
• W2004149792 countsByYear W20041497922022 @default.
• W2004149792 countsByYear W20041497922023 @default.
• W2004149792 crossrefType "journal-article" @default.
• W2004149792 hasAuthorship W2004149792A5000210931 @default.
• W2004149792 hasAuthorship W2004149792A5020507966 @default.
• W2004149792 hasAuthorship W2004149792A5027612338 @default.
• W2004149792 hasAuthorship W2004149792A5028693685 @default.
• W2004149792 hasAuthorship W2004149792A5029874460 @default.
• W2004149792 hasAuthorship W2004149792A5036158155 @default.
• W2004149792 hasAuthorship W2004149792A5037248383 @default.
• W2004149792 hasAuthorship W2004149792A5053583284 @default.
• W2004149792 hasAuthorship W2004149792A5055180780 @default.
• W2004149792 hasAuthorship W2004149792A5060906323 @default.
• W2004149792 hasAuthorship W2004149792A5070113073 @default.
• W2004149792 hasAuthorship W2004149792A5079738832 @default.
• W2004149792 hasAuthorship W2004149792A5080140512 @default.
• W2004149792 hasAuthorship W2004149792A5091090377 @default.
• W2004149792 hasBestOaLocation W20041497921 @default.
• W2004149792 hasConcept C115961737 @default.
• W2004149792 hasConcept C126322002 @default.
• W2004149792 hasConcept C197934379 @default.
• W2004149792 hasConcept C198451711 @default.
• W2004149792 hasConcept C2777077863 @default.
• W2004149792 hasConcept C2777288759 @default.
• W2004149792 hasConcept C2779134260 @default.

• next